Trial Profile
A Phase 1-2 Ascending Dose Study To Assess The Pharmacodynamics, Pharmacokinetics, And Safety Of Hsp-130 In Subjects With Non-metastatic Breast Cancer Following Single-dose And Multiple-dose Administration By Subcutaneous Injection
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jan 2022
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Hospira; Pfizer
- 01 Dec 2021 Results published in the Cancer Chemotherapy and Pharmacology
- 21 Nov 2017 Status changed from recruiting to completed.
- 03 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.